Clinical Trials in Maryland

Showing 5181-5200 of 23,284 trials

Evaluation of Global Smart Drinking Goals Initiative

NCT03262259

This study will evaluate effects of a multi-component, population-level intervention on alcohol use and related harms in six intervention cities relative to six matched comparison cities. Intervention components include screening and brief interventions by health providers, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation. Key outcomes of interest include alcohol-related harms such as alcohol-related motor vehicle crashes and fatalities, heavy/binge drinking, underage drinking, and drinking and driving.

Binge Drinking, Underage Drinking, Drinking and Driving, Alcohol-Related Harms

HBSA36,000 participantsStarted Sep 2017

Calverton, Maryland, United States

COMPLETEDPhase 217 miles

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

NCT04629508

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

MyelofibrosisPolycythemia VeraThrombocythemia

Incyte Corporation4 participantsStarted Jul 2021

New Orleans, Louisiana, United States • Bethesda, Maryland, United States • Kansas City, Missouri, United States +18 more locations

Evaluation of Global Smart Drinking Goals Initiative

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Find Trials by Condition in Maryland

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Virtual Group Psychoeducational Discussions With Spanish-Speaking Mothers of Infants in Pediatric Primary Care

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

MR Image Synthesis With Low Gadobutrol Dose and AI

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

A Study of Abemaciclib in Recurrent Glioblastoma

CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM